Trieste Researchers Identify Rare SF3B3 Genetic Disorder: Diagnosis Now Possible for Families

The Italy-based IRCCS Burlo Garofolo institute has led international researchers in pinpointing a previously unknown genetic disorder—a spliceosomopathy triggered by mutations in the SF3B3 gene—that now opens pathways for diagnosis and future therapies for families navigating rare neurodevelopmental conditions. The findings, published in the February 2026 edition of Genome Medicine, establish SF3B3 as the first human disease gene in its class and provide a diagnostic anchor for 24 documented cases worldwide, including patients enrolled at the maternal-child health institute in Trieste.

Why This Matters

• Diagnosis is now possible: Families with unexplained developmental delays, autism traits, and multiple congenital anomalies can pursue SF3B3 genetic screening through national health channels.

• Global disease registry entry: The discovery qualifies for inclusion in OMIM (Online Mendelian Inheritance in Man), the international catalog of genetic disorders, ensuring clinical recognition.

• Therapeutic research starts here: Understanding splicing defects in SF3B3 positions Italy at the forefront of RNA-modulation therapies currently in trials for similar conditions like cystic fibrosis.

Impact on Residents and Families: Practical Access Through Italy's Health System

For families in Italy—especially those cycling through regional genetic clinics in Friuli Venezia Giulia, Piedmont, and Emilia-Romagna—this discovery translates into actionable diagnostic clarity. Previously, children presenting with unexplained developmental regression, speech delays, and congenital heart or urogenital anomalies often faced years of inconclusive consultations.

When to suspect SF3B3: Consult your pediatrician if your child shows a combination of developmental delays (reaching milestones later than peers), language or motor impairments, intellectual disability, facial or body feature variations, or autism spectrum traits—especially if multiple family members are affected or if symptoms began without a clear cause.

How to access testing through the SSN:

• Pediatricians can refer suspected cases to accredited genetic laboratories at university hospitals in Trieste, Udine, Turin, Rome, or Milan

• Genetic testing is zero cost to families—covered entirely by the national health system (Servizio Sanitario Nazionale, SSN)

• Because SF3B3-linked spliceosomopathy qualifies as a rare disease under the Italian National Rare Diseases Plan, families receive co-payment exemptions for specialist visits, genetic counseling, and rehabilitative therapies (speech, occupational, physical) coordinated through regional centers of expertise (Centri di Riferimento Regionale)

• Typical wait time for results: 2-4 weeks after sample collection through SSN laboratories

A targeted genetic panel including SF3B3 can confirm or exclude the diagnosis within weeks, ending what patient advocates call "the diagnostic odyssey."

What SF3B3 Does—And Why It Goes Wrong

SF3B3 encodes a subunit of the SF3b spliceosomal complex, a molecular machine that edits messenger RNA before cells manufacture proteins. Think of splicing as a genetic "copy-editing" step: cells remove non-coding segments (introns) and stitch together coding segments (exons) to produce a final protein blueprint.

When SF3B3 malfunctions due to inherited mutations—specifically missense variants following an autosomal dominant pattern (meaning inheriting one faulty copy from either parent is enough to cause the condition)—the editing process derails. Patient-derived fibroblast studies revealed reduced SF3B3 protein levels, impaired binding to partner molecules, and widespread transcriptome chaos, including abnormally retained introns and cell-cycle disruptions.

The clinical fallout is severe. Luciana Musante, geneticist at Burlo Garofolo and lead author of the study, describes a spectrum from perinatal lethality in the most extreme prenatal forms to survivable presentations marked by developmental delays, language and motor impairments, intellectual disability, and craniofacial dysmorphology. "In a subset of young patients we also observe autism spectrum traits," Musante notes, underscoring the variable penetrance that complicates early detection.

How the Discovery Unfolded

The investigation began with a single patient enrolled at the Trieste institute. Standard genetic sequencing flagged a variant in SF3B3, a gene never before implicated in human disease. To validate the finding, Musante and co-coordinator Flavio Faletra—a geneticist at the Friuli Venezia Giulia regional health authority (ASUFC) and the University of Udine—launched an international data-sharing initiative. Within months, the team had assembled molecular and clinical data from 24 unrelated individuals across three continents.

Collaborating institutions spanned Germany (Heidelberg, Munich), Canada (Toronto), Iceland (deCODE genetics/Amgen), the Netherlands (Utrecht), Switzerland (Lugano), and the United States (Boston, Chapel Hill, Cambridge). Italian partners included the CNR Istituto Officina dei Materiali (IOM), the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, and pediatric neurology units in Turin. The multinational cohort allowed researchers to define a consistent phenotypic signature and rule out chance association.

Therapeutic Horizon: RNA-Modulation Strategies

While no curative treatment yet exists for SF3B3 spliceosomopathy, the research positions Italy to participate in next-generation RNA-targeted trials. Pharmaceutical groups including GSK are advancing exon-specific U1 snRNA (ExSpeU1) constructs (specialized molecules designed to fix faulty RNA editing) and antisense oligonucleotides (ASOs) (short DNA-like chains that redirect how cells process genetic instructions) designed to correct aberrant splicing. Early-stage experiments in cystic fibrosis—where splice mutations account for 12% of cases—have restored normal mRNA production in cultured cells using ExSpeU1, and the FDA-approved drug elexacaftor/tezacaftor/ivacaftor (Trikafta) now covers 177 CFTR mutations responsive to splice modulation.

Applying similar logic to SF3B3, researchers envision targeted bifunctional oligonucleotide enhancers of splicing (TOES) or CRISPR-Cas13 systems to guide RNA-binding proteins toward corrective sites. The ICGEB's molecular biology infrastructure in Trieste—already equipped for high-throughput transcriptome profiling—positions the Burlo team to screen candidate compounds in patient-derived cell lines.

Quality of Life and Support Networks

Understanding the prognosis: The syndrome's variable severity means outcomes diverge sharply. Perinatal-lethal forms present with catastrophic organ malformations detectable via prenatal ultrasound, triggering difficult counseling conversations. Milder phenotypes permit survival into adulthood, contingent on intensive early intervention.

Key support resources and services for families:

• Autonomy and daily care: Intellectual disability and motor delays often preclude independent living; most patients require lifelong caregiver support for feeding, hygiene, and household tasks. Apply for Legge 104/1992 benefits through your regional social services office to access caregiver support and tax deductions.

• Education: Language impairments and autism traits complicate mainstream schooling. Under Italian law, your child is entitled to individualized education plans (IEP) and specialized support teachers (insegnanti di sostegno). Request these through your school's disability coordinator (GLO - Gruppo di Lavoro Operativo).

• Disability and financial support: Families may qualify for indennità di accompagnamento (carer's allowance) and disability pension through INPS (Agenzia delle Entrate). Contact your local INPS office or consult a legal advisor specializing in disability benefits.

• Social integration: Isolation and loneliness are common; peer friendship networks remain sparse beyond structured therapeutic settings. Patient advocacy groups such as Uniamo FIMR (Italian Federation for Rare Diseases) provide information portals, legal guidance, and connections to specialized rehabilitation centers. Multidisciplinary follow-up—pediatric neurologist, cardiologist, urologist, developmental psychologist—is essential to monitor cardiac or genitourinary anomalies and adjust behavioral interventions.

• Family burden support: Navigating the SSN, regional disability services, and school inclusion coordinators consumes parental bandwidth. Many caregivers benefit from peer support networks; ask your regional rare disease center about caregiver support groups.

Next Steps: OMIM Registration and Expanded Cohorts

Publication in Genome Medicine and the 24-patient cohort size satisfy criteria for entry into OMIM, the authoritative compendium maintained by Johns Hopkins University. Registration assigns a unique OMIM number, enabling global diagnostic laboratories to flag SF3B3 variants in routine exome or genome reports. Italian reference labs—including those at Bambino Gesù (Rome), Meyer (Florence), and Gaslini (Genoa)—are updating gene panels accordingly.

The Burlo team is now recruiting additional families through GeneMatcher, an international platform that connects clinicians encountering ultra-rare variants. Expanded cohorts will refine genotype-phenotype correlations, clarify recurrence risks, and stratify patients for future clinical trials. Musante emphasizes that "every new family we identify sharpens our understanding of the splicing defects and their downstream consequences, bringing us closer to rational therapeutic design."

How to Learn More and Get Help

For Italy's rare-disease community, the SF3B3 discovery underscores the value of centralized data sharing and the strategic role of specialized pediatric institutes in driving global genetic medicine. Families seeking more information can:

• Contact the Burlo Garofolo Genetic Counseling Unit (Tel: +39 040 3785 111; Email: genetica@burlo.trieste.it)

• Visit the Orphanet Italy portal (www.orpha.net) for updated clinical summaries and trial registries

• Reach out to Uniamo FIMR for patient advocacy support and resource connections

• Ask your pediatrician for a referral to the nearest regional rare disease diagnostic center